Dafinchi AI

Alignment Healthcare, Inc.

ALHC

Healthcare

2w

Financial Performance Summary

Adjusted EBITDA was $46 million in Q2, surpassing guidance range of $10 million to $18 million, with a margin of 4.5%, expanding 360 basis points year-over-year.
Adjusted gross profit was $135 million, a 76% increase year-over-year, with a consolidated MBR of 86.7%, improving by 200 basis points.
Adjusted SG&A ratio improved by 160 basis points year-over-year to 8.8%.
Balance sheet ended Q2 with $504 million in cash, cash equivalents, and investments.
First half 2025 adjusted EBITDA was $66 million, exceeding the high end of initial full year guidance ($35 million to $60 million).
Health plan membership reached 223,700 members in Q2 2025, a 28% year-over-year increase.
Total revenue for Q2 2025 was $1 billion, up approximately 49% year-over-year.

Select Medical Holdings Corporation

SEM

Healthcare

2w

Recognition of Top-Ranked Rehabilitation Hospitals and Strategic Development Achievements

Eight hospitals recognized among the nation's best by U.S. News & World Report, with Kessler Institute for Rehabilitation ranked #4 for 33rd consecutive year.
Opened new facilities including a 12-bed hospital with UPMC in Pennsylvania, a neuro transitional care unit in Missouri, and expansions in Florida.
Plans to open multiple new hospitals in 2026 and 2027, including partnerships with Banner Health and Cox Health Systems, with a focus on high-demand markets.

Insmed Incorporated

INSM

Healthcare

1w

Financial Performance Summary

ARIKAYCE delivered double-digit year-over-year revenue growth globally, with the highest quarterly revenue ever achieved in the United States.
Cash balance increased to approximately $1.9 billion following a $823 million net proceeds equity offering.
Cost of product revenues was $28.1 million or 26.1% of revenues, slightly higher due to increased international sales proportion.
Europe sales grew 48%, primarily due to strong demand in Germany, Switzerland, and Austria.
Full year 2025 ARIKAYCE net revenue guidance remains $405 million to $425 million.
Japan sales grew 45% driven by new targeting strategies and improved patient experience.
Operating expenses increased due to investments in commercial readiness for brensocatib and pipeline funding.

Thermo Fisher Scientific Inc.

TMO

Healthcare

3w

Financial Performance Summary

Adjusted EPS was $5.36, beating guidance, with GAAP EPS at $4.28, up 6% year-over-year.
Adjusted gross margin was 41.3%, down 80 basis points year-over-year due to tariffs and FX.
Adjusted ROIC was 11.3%, reflecting strong returns on investment.
Adjusted SG&A was 16.2% of revenue; R&D expense was $352 million (7.4% of manufacturing revenue).
Free cash flow was $1.5 billion after $645 million in capital expenditures; ended quarter with $6.4 billion cash and $35.2 billion debt.
Free cash flow was $1.5 billion after $645 million in capital expenditures; leverage ratio was 3.2x gross debt to adjusted EBITDA.
Leverage ratio was 3.2x gross debt to adjusted EBITDA and 2.7x net debt to EBITDA.
Organic revenue growth was 2%, with a 1% contribution from acquisitions and a 1% FX tailwind.
Q2 revenue grew 3% to $10.85 billion, adjusted operating income grew 1% to $2.38 billion, with an adjusted operating margin of 21.9%.
Q2 revenue grew 3% to $10.85 billion, adjusted operating income increased 1% to $2.38 billion, with an adjusted operating margin of 21.9%.
Segment performance: Life Sciences Solutions revenue up 6% with 4% organic growth; Analytical Instruments revenue declined 3% with 4% organic decline; Specialty Diagnostics revenue grew 2% with flat organic growth; Laboratory Products and Biopharma Services revenue increased 4% with 3% organic growth.
Segment performance varied: Life Sciences Solutions grew 6% reported and 4% organic; Analytical Instruments revenue declined 3%; Specialty Diagnostics grew 2%; Laboratory Products and Biopharma Services grew 4%.
Tariffs and FX negatively impacted margins by 140 basis points, partially offset by productivity gains.